Repligen Corp RGEN
We take great care to ensure that the data presented and summarized in this overview for REPLIGEN CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RGEN
View all-
Black Rock Inc. New York, NY7.57MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$769 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.51MShares$534 Million0.05% of portfolio
-
United Capital Financial Advisers, LLC Newport Beach, CA2.76MShares$420 Million2.74% of portfolio
-
State Street Corp Boston, MA1.8MShares$275 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.68MShares$257 Million0.04% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.44MShares$220 Million0.38% of portfolio
-
Holocene Advisors, LP New York, NY1.38MShares$210 Million0.45% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.34MShares$204 Million1.41% of portfolio
-
Alliancebernstein L.P. New York, NY1.1MShares$168 Million0.05% of portfolio
Latest Institutional Activity in RGEN
Top Purchases
Top Sells
About RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Insider Transactions at RGEN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2025
|
Anthony Hunt |
SELL
Other acquisition or disposition
|
Direct |
2,000
-1.98%
|
-
|
|
Nov 25
2025
|
Olivier Loeillot Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,041
-16.4%
|
$1,196,970
$170.0 P/Share
|
|
Nov 18
2025
|
James Bylund Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,191
-9.24%
|
$330,841
$151.21 P/Share
|
|
Nov 13
2025
|
Anthony Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
2,952
+3.41%
|
$97,416
$33.87 P/Share
|
|
Nov 13
2025
|
Anthony Hunt |
SELL
Open market or private sale
|
Direct |
20,000
-3.1%
|
$3,080,000
$154.2 P/Share
|
|
Nov 12
2025
|
Anthony Hunt |
SELL
Open market or private sale
|
Direct |
25,000
-4.29%
|
$3,900,000
$156.79 P/Share
|
|
Nov 12
2025
|
Anthony Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+16.58%
|
$825,000
$33.87 P/Share
|
|
Oct 02
2025
|
Olivier Loeillot Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,248
-2.82%
|
$180,960
$145.23 P/Share
|
|
Sep 25
2025
|
Jason K Garland CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
412
-2.99%
|
$49,852
$121.68 P/Share
|
|
Sep 10
2025
|
Anthony Hunt |
SELL
Open market or private sale
|
Direct |
29,111
-4.05%
|
$3,464,209
$119.69 P/Share
|
|
Sep 10
2025
|
Anthony Hunt |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+13.35%
|
$660,000
$33.87 P/Share
|
|
Sep 03
2025
|
Olivier Loeillot Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,506
-5.37%
|
$290,696
$116.18 P/Share
|
|
Sep 02
2025
|
Violetta Hughes CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,142
+50.0%
|
-
|
|
Aug 08
2025
|
Martin D Madaus |
BUY
Open market or private purchase
|
Indirect |
1,800
+50.0%
|
$201,600
$112.13 P/Share
|
|
May 15
2025
|
Nicolas Barthelemy |
BUY
Grant, award, or other acquisition
|
Direct |
973
+17.97%
|
-
|
|
May 15
2025
|
Konstantin Konstantinov |
BUY
Grant, award, or other acquisition
|
Direct |
973
+25.16%
|
-
|
|
May 15
2025
|
Manner Carrie Eglinton |
BUY
Grant, award, or other acquisition
|
Direct |
973
+17.89%
|
-
|
|
May 15
2025
|
Glenn P Muir |
BUY
Grant, award, or other acquisition
|
Direct |
973
+2.84%
|
-
|
|
May 15
2025
|
Karen A Dawes |
BUY
Grant, award, or other acquisition
|
Direct |
973
+1.05%
|
-
|
|
May 15
2025
|
Martin D Madaus |
BUY
Grant, award, or other acquisition
|
Direct |
973
+14.83%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 74.7K shares |
|---|---|
| Grant, award, or other acquisition | 44.5K shares |
| Open market or private purchase | 2.05K shares |
| Payment of exercise price or tax liability | 24.9K shares |
|---|---|
| Other acquisition or disposition | 2K shares |
| Open market or private sale | 137K shares |